摘要
目的研究重组人脑钠肽(rhBNP)治疗对急性心肌梗死(AMI)患者经皮冠状动脉介入治疗(PCI)术后的影响。方法选取2020年7月至2023年5月接受PCI的AMI患者110例,根据术后用药情况分为:对照组(n=55,术后采用常规用药)和研究组(n=55,在对照组用药方案基础上加用重组rhBNP)。比较两组患者治疗前后心脏功能和血清炎症因子的差异。PCI术后进行6个月随访,记录随访期间主要不良事件(MACE)发生情况。结果两组患者治疗前左室舒张期内径(LVEDD)、室间隔厚度(IVS)、左室舒末期内径(LVD)、左室射血分数(LVEF)、左室短轴缩短率(FS)、肌酸激酶同工酶(CK-MB)、肌钙蛋白T(cTnT)、肌钙蛋白I(cTnI)、心型脂肪酸结合蛋白(H-FABP)、白介素-6(IL-6)、IL-8、肿瘤坏死因子-α(TNF-α)比较,均无统计学差异(P>0.05);两组患者治疗后LVEDD、IVS、LVD和血清CK-MB、cTnT、cTnI、H-FABP、IL-6、IL-8、TNF-α比较,均较治疗前显著降低(P<0.05),而LVEF和FS均较治疗前显著升高(P<0.05)。治疗后,研究组患者LVEDD、IVS、LVD和血清CK-MB、cTnT、cTnI、H-FABP、IL-6、IL-8、TNF-α均显著低于对照组(P<0.05),而LVEF和FS均显著高于对照组(P<0.05)。研究组患者PCI术后半年内MACE发生率显著低于对照组(18.18%vs.50.91%,P<0.05)。结论AMI患者PCI术后应用重组人脑利钠肽治疗可显著改善心肌损伤,抑制心室重构和炎症,降低PCI术后MACE发生率。
Objective To investigate the effect of recombinant human brain natriuretic peptide therapy on patients with acute myocardial infarction(AMI)after percutaneous coronary intervention(PCI).Methods A total of 110 AMI patients who received PCI surgery from July 2020 to May 2023 were selected.According to the postoperative medication regime,55 patients in the control group received routine medication after surgery,and 55 patients in the study group were treated with recombinant human brain natriuretic peptide in addition to the control group's medication regimen.Cardiac function and serum inflammatory factors were compared between the two groups before and after treatment.Major adverse events(MACE)were recorded during the 6-month follow-up after PCI.Results Before treatment,there were no differences in left ventricular diastolic diameter(LVEDD),interventricular septal thickness(IVS),left ventricular end-diastolic diameter(LVD),left ventricular ejection fraction(LVEF),fraction shortening(FS),creatine kinase isoenzyme(CK-MB),troponin T(cTnT),troponin I(cTnI),heart fatty acid binding protein(H-FABP),interleukin-6(IL-6),IL-8 and tumor necrosis factor-αbetween the two groups.After treatment,LVEDD,IVS,LVD,and serum levels of CK-MB,cTnT,cTnI,H-FABP,IL-6,IL8,and TNF-αdecreased significantly in both groups compared to pretreatment levels(P<0.05),while LVEF and FS increased significantly(P<0.05).Moreover,post-treatment,these parameters(LVEDD,IVS,LVD,and serum markers)were significantly lower in the study group than in the control group(P<0.05),while LVEF and FS were significantly higher in the study group(P<0.05).The incidence of MACEs six months after PCI was significantly lower in the study group than in the control group(18.18%vs.50.91%,P<0.05).Conclusion Treatment with recombinant human brain natriuretic peptide after PCI in AMI patients can significantly improve myocardial injury,inhibit ventricular remodeling and inflammation,and reduce the incidence of MACEs after PCI.
作者
孟宪磊
刘俊飞
任建明
安炎霞
Meng Xianlei;Liu Junfei;Ren Jianming;An Yanxia(Department of Cardiology,Luoyang First People's Hospital,Luoyang,Henan,471002)
出处
《中国循证心血管医学杂志》
2025年第2期185-188,共4页
Chinese Journal of Evidence-Based Cardiovascular Medicine
基金
河南省医学科技攻关计划项目(GJ202309081316)。
